V
VenatoRx Pharmaceuticals
Discovering and developing novel anti-infectives to treat multi-drug resistant bacterial and hard-to-treat viral infections
About VenatoRx Pharmaceuticals
Venatorx Pharmaceuticals is a private company specializing in the discovery and development of novel anti-infectives aimed at treating multi-drug resistant (MDR) bacterial infections and challenging viral infections. Based near Philadelphia, Pennsylvania, Venatorx operates in the pharmaceutical sector with a strong focus on infectious diseases. The company collaborates with global partners such as GARDP to develop new antibiotics for hospital-acquired infections that have limited treatment options. Venatorx's business model revolves around research and development (R&D) of new drugs, which are then brought to market through partnerships, licensing agreements, and direct sales. Revenue is generated through these collaborations, grants, and eventual product sales. The company serves healthcare providers, hospitals, and research institutions that require advanced solutions for combating resistant infections. Venatorx's commitment to innovation and its strategic partnerships position it as a leader in the anti-infective pharmaceutical market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Malvern, United States
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 28.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Mar 2023 | $16M | — | Undisclosed | ↗ |
| LATE VCOther financing | Sep 2022 | $24M | $210M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for VenatoRx Pharmaceuticals is 2.3K monthly website visits, up 27.8% over the last three months. VenatoRx Pharmaceuticals's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
National Institutes of Health
US Defense Threat Reduction Agency
US National Institute of Allergy and Infectious Diseases
CARB-X
Series A4 investors entered at this stage
BioAdvance
Versant Ventures
Foresite Capital
Abingworth
Series B and later1 investor entered at this stage
AMR Action Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about VenatoRx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VenatoRx Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.